Bristol-Myers Squibb Co. looks set to make a mark in treating classical Hodgkin lymphoma: it has announced new data showing positive results for its immune-oncology therapy Opdivo in previously treated HL patients supporting the use of checkpoint inhibitors blood cancers as well as solid tumors.
The CheckMate -205 study evaluates Opdivo in patients with classical Hodgkin lymphoma (HL) and the data revealed by BMS focuses...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?